OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone305-575-4100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$990.30 million
Profitability
Miscellaneous
Employees5,690
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Opko Health (NASDAQ:OPK) Frequently Asked Questions
What is Opko Health's stock symbol?
Opko Health trades on the NASDAQ under the ticker symbol "OPK."
How were Opko Health's earnings last quarter?
Opko Health Inc. (NASDAQ:OPK) announced its quarterly earnings results on Wednesday, August, 7th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The biotechnology company had revenue of $226.40 million for the quarter, compared to the consensus estimate of $225.07 million. Opko Health had a negative net margin of 26.55% and a negative return on equity of 12.17%. Opko Health's revenue for the quarter was down 14.1% on a year-over-year basis. During the same period last year, the company posted ($0.01) EPS. View Opko Health's Earnings History.
When is Opko Health's next earnings date?
What price target have analysts set for OPK?
1 Wall Street analysts have issued 12-month target prices for Opko Health's shares. Their predictions range from $5.00 to $5.00. On average, they anticipate Opko Health's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 173.2% from the stock's current price. View Analyst Price Targets for Opko Health.
What is the consensus analysts' recommendation for Opko Health?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opko Health.
What are Wall Street analysts saying about Opko Health stock?
Here are some recent quotes from research analysts about Opko Health stock:
- 1. According to Zacks Investment Research, "OPKO Health has gained significantly from RAYALDEE contribution in recent times. Further, OPKO Health’s utilization of the 4Kscore remains strong, with nearly 18,800 tests registered in the second quarter. These apart, the company’s clinical development programs look promising with a robust pipeline of candidates. Several metabolic and endocrinology programs that are underway should provide OPKO Health a competitive advantage. However, the company’s gross margin is under pressure at the moment. Moreover, the company faces cutthroat competition in the MedTech space. Sluggishness in the Services revenue segment remains a concern. OPKO Health underperformed its industry in a year’s time. With respect to quarterly results, OPKO Health exited the second quarter on a strong note." (8/20/2019)
- 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on OPK shares but are reducing our 12-month price target to $5 from $7. Even given the reduced target, price appreciation potential remains at approximately 80%, hence our constructive rating. We arrive at our price target via a DCF methodology for its current commercial business plus the hGH-CTP program. We assign an additional $1 of value for the remainder of OPKO’s product pipeline." (2/28/2019)
Has Opko Health been receiving favorable news coverage?
News articles about OPK stock have trended positive on Sunday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Opko Health earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for Opko Health.
Who are some of Opko Health's key competitors?
Some companies that are related to Opko Health include GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), FibroGen (FGEN), Allakos (ALLK), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Alkermes (ALKS), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Taro Pharmaceutical Industries (TARO), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR) and The Medicines (MDCO).
What other stocks do shareholders of Opko Health own?
Who are Opko Health's key executives?
Opko Health's management team includes the folowing people:
- Dr. Phillip Frost, Chairman & CEO (Age 83)
- Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 72)
- Mr. Adam E. Logal, Sr. VP, CFO, Chief Accounting Officer & Treasurer (Age 41)
- Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 59)
- Ms. Kate Inman, Gen. Counsel & Sec. (Age 46)
Who are Opko Health's major shareholders?
Opko Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.12%), Vanguard Group Inc. (4.95%), Northern Trust Corp (0.68%), Charles Schwab Investment Management Inc. (0.39%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.34%) and Panagora Asset Management Inc. (0.32%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for Opko Health.
Which major investors are selling Opko Health stock?
OPK stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Invesco Ltd., Morgan Stanley, Canada Pension Plan Investment Board, Marshall Wace LLP, Bank of America Corp DE, Prudential Financial Inc. and D. E. Shaw & Co. Inc.. View Insider Buying and Selling for Opko Health.
Which major investors are buying Opko Health stock?
OPK stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Asymmetry Capital Management L.P., BlackRock Inc., Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Vanguard Group Inc., JPMorgan Chase & Co., Balyasny Asset Management LLC and Teton Advisors Inc.. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for Opko Health.
How do I buy shares of Opko Health?
Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Opko Health's stock price today?
One share of OPK stock can currently be purchased for approximately $1.83.
How big of a company is Opko Health?
Opko Health has a market capitalization of $1.13 billion and generates $990.30 million in revenue each year. The biotechnology company earns $-153,040,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Opko Health employs 5,690 workers across the globe.View Additional Information About Opko Health.
What is Opko Health's official website?
How can I contact Opko Health?
Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]
MarketBeat Community Rating for Opko Health (NASDAQ OPK)
MarketBeat's community ratings are surveys of what our community members think about Opko Health and other stocks. Vote "Outperform" if you believe OPK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPK will underperform the S&P 500 over the long term. You may vote once every thirty days.
